Sheng Yin

Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial

Tingyan Shi, Jianqing Zhu, Yanling Feng et al. · The Lancet Oncology · 2021 · 211 citations

Chemotherapy Versus Chemotherapy, Secondary Cytoreduction, Medicine +7

<i>BRCA1</i> and <i>BRCA2</i> mutations in ovarian cancer patients from China: ethnic‐related mutations in <i>BRCA1</i> associated with an increased risk of ovarian cancer

Tingyan Shi, Pan Wang, Caixia Xie et al. · International Journal of Cancer · 2017 · 61 citations · Full text

Brca1/2 Genetic Testing, Breast Oncology, Cancer Risk +15

Radical surgery versus standard surgery for primary cytoreduction of bulky stage IIIC and IV ovarian cancer: an observational study

Rong Jiang, Sheng Yin, Chao You et al. · BMC Cancer · 2015 · 50 citations · Full text

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Rongyu Zang, Jianqing Zhu, Tingyan Shi et al. · Journal of Clinical Oncology · 2020 · 42 citations

Secondary Cytoreductive Surgery, Surgical Oncology, Prehabilitation +15

Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept

Rong Jiang, Jianqing Zhu, Jae‐Weon Kim et al. · Journal of Gynecologic Oncology · 2020 · 41 citations · Full text